Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Colorcon
Medtronic
Mallinckrodt
Harvard Business School

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYMBALTA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Cymbalta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00105989 ↗ Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed Boehringer Ingelheim Phase 3 2005-03-01 The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00105989 ↗ Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed Eli Lilly and Company Phase 3 2005-03-01 The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00114127 ↗ Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed Massachusetts General Hospital Phase 3 2004-06-01 The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
NCT00177671 ↗ Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed National Institute of Mental Health (NIMH) Phase 4 2003-12-01 This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
NCT00177671 ↗ Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed University of Pittsburgh Phase 4 2003-12-01 This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
NCT00185575 ↗ Duloxetine for the Treatment of Dysthymia Completed Eli Lilly and Company N/A 2004-09-01 The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cymbalta

Condition Name

Condition Name for Cymbalta
Intervention Trials
Major Depressive Disorder 22
Depression 15
Fibromyalgia 9
Generalized Anxiety Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cymbalta
Intervention Trials
Depression 48
Depressive Disorder 44
Depressive Disorder, Major 33
Disease 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cymbalta

Trials by Country

Trials by Country for Cymbalta
Location Trials
United States 505
Canada 29
Germany 12
France 12
United Kingdom 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cymbalta
Location Trials
New York 30
California 27
Florida 25
Ohio 24
Texas 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cymbalta

Clinical Trial Phase

Clinical Trial Phase for Cymbalta
Clinical Trial Phase Trials
Phase 4 57
Phase 3 36
Phase 2/Phase 3 3
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cymbalta
Clinical Trial Phase Trials
Completed 100
Recruiting 13
Unknown status 9
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cymbalta

Sponsor Name

Sponsor Name for Cymbalta
Sponsor Trials
Eli Lilly and Company 67
Boehringer Ingelheim 12
Shionogi 8
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cymbalta
Sponsor Trials
Industry 104
Other 97
NIH 10
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Baxter
Moodys
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.